US EditionGSK’s boss Emma Walmsley to step down after eight-year tenure
Luke Miels will lead GSK from 2026, aiming to overcome patent expirations and market challenges while pursuing over £40 billion in sales by 2031, the company said.
- GSK announced that Dame Emma Walmsley will step down as CEO after eight years, with Luke Miels succeeding her in 2026, as the company stated.
- Following the announcement, GSK shares increased by 3.5%, reaching a three-month high.
- Walmsley highlighted that 2026 is crucial for GSK to define its future, stating she believes it is the right time for new leadership.
- Chair Sir Jonathan Symonds thanked Walmsley for her outstanding leadership, particularly for the successful demerger of Haleon in 2022.
54 Articles
54 Articles
Leadership Changes and Bold Moves Shake Global Drugmakers
Leadership Changes and Bold Moves Shake Global Drugmakers In a surprising turn of events, British pharmaceutical giant GSK has named insider Luke Miels as the successor to CEO Emma Walmsley, who is stepping down after a significant tenure. The move underscores the company's intent to enhance its pipeline amid U.S. trade tariff challenges.Meanwhile, Kala Bio's stock took a drastic 93% fall in premarket trading following the announcement that its …
GSK's Emma Walmsley to step down as CEO in shock move, giving way to commercial lead Luke Miels
The first woman to helm a Big Pharma will be stepping down in January as GSK’s Emma Walmsley moves aside for her chief commercial officer Luke Miels. Walmsley, 56, who became the British pharma’s CEO back in 2017, will officially leave Jan. 1, 2026, after turning around the fortunes of GSK in…
Coverage Details
Bias Distribution
- 48% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
